WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Results published this week in The Lancet show that Merck’s cervical cancer vaccine, GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] was 100 percent effective in preventing high-grade vulvar and vaginal dysplasias caused by HPV types 16 and 18, two types strongly associated with these diseases. The 100 percent protection was observed in women who were not infected with HPV types targeted by the vaccine -- 6, 11, 16 and 18 -- at the start of the study and through one month after receiving the third dose. Data published in The Lancet represent an additional year of follow up since data were presented to the U.S. Food and Drug Administration (FDA) for approval of GARDASIL.
